Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHEREXA: Pertuzumab + Trastuzumab + Capecitabine in HER2+ Metastatic Breast Cancer
NCT01026142Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2010
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of pertuzumab in HER2-positive breast cancer, sponsored by Roche. Started Jan 2010; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01026142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026142.